HRP20090438T1 - Peroral formulation of dienogest and ethinylestradiol for contraception - Google Patents

Peroral formulation of dienogest and ethinylestradiol for contraception

Info

Publication number
HRP20090438T1
HRP20090438T1 HR20090438T HRP20090438T HRP20090438T1 HR P20090438 T1 HRP20090438 T1 HR P20090438T1 HR 20090438 T HR20090438 T HR 20090438T HR P20090438 T HRP20090438 T HR P20090438T HR P20090438 T1 HRP20090438 T1 HR P20090438T1
Authority
HR
Croatia
Prior art keywords
dienogest
ethinylestradiol
contraception
peroral formulation
ethynyloestradiol
Prior art date
Application number
HR20090438T
Other languages
Croatian (hr)
Inventor
Gerecke Hagen
Ladwig Ralf
Wiesinger Herbert
Fricke Sabine
Buske Alexander
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20090438T1 publication Critical patent/HRP20090438T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Peroralni oblik lijeka za kontracepciju, koji sadrži 17α-cijanometil-17ß-hidroksioestra-4,9-dien-3-on (dienogest) u količini jednakoj ili manjoj od 2.0 mg i 17α-etiniloestradiol (etiniloestradiol) u količini manjoj od 0.030 mg, naznačen time da je kristalni aktivni spoj dienogest prisutan sa prosječnom veličinom čestica 30 do 270 µm. Patent sadrži još 4 patentna zahtjeva.An oral form of contraceptive containing 17α-cyanomethyl-17β-hydroxyeoester-4,9-dien-3-one (dienogest) in an amount equal to or less than 2.0 mg and 17α-ethynyloestradiol (ethynyloestradiol) in an amount less than 0.030 mg, wherein the crystalline active compound dienogest is present with an average particle size of 30 to 270 μm. The patent contains 4 more patent claims.

HR20090438T 2006-08-10 2009-08-13 Peroral formulation of dienogest and ethinylestradiol for contraception HRP20090438T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06016694A EP1886694B1 (en) 2006-08-10 2006-08-10 Peroral formulation of dienogest and ethinylestradiol for contraception

Publications (1)

Publication Number Publication Date
HRP20090438T1 true HRP20090438T1 (en) 2009-09-30

Family

ID=37561777

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090438T HRP20090438T1 (en) 2006-08-10 2009-08-13 Peroral formulation of dienogest and ethinylestradiol for contraception

Country Status (18)

Country Link
EP (1) EP1886694B1 (en)
AR (1) AR062323A1 (en)
AT (1) ATE432714T1 (en)
CL (1) CL2007002323A1 (en)
CY (1) CY1110348T1 (en)
DE (1) DE502006003892D1 (en)
DK (1) DK1886694T3 (en)
DO (1) DOP2007000122A (en)
ES (1) ES2327665T3 (en)
HR (1) HRP20090438T1 (en)
NO (1) NO20091057L (en)
PE (1) PE20080541A1 (en)
PL (1) PL1886694T3 (en)
PT (1) PT1886694E (en)
SI (1) SI1886694T1 (en)
TW (1) TW200817012A (en)
UY (1) UY30530A1 (en)
WO (1) WO2008017331A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010003711B4 (en) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Process for the preparation of crystalline active substance particles
CN115487198B (en) * 2022-09-20 2024-01-02 华中药业股份有限公司 Levonorgestrel preparation with fast dissolution rate and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
DE10218107A1 (en) * 2002-04-23 2003-11-20 Jenapharm Gmbh Process for the production of crystals of steroids, crystals available thereafter and their use in pharmaceutical formulations

Also Published As

Publication number Publication date
NO20091057L (en) 2009-03-09
ATE432714T1 (en) 2009-06-15
DOP2007000122A (en) 2008-02-15
TW200817012A (en) 2008-04-16
PE20080541A1 (en) 2008-07-10
DE502006003892D1 (en) 2009-07-16
UY30530A1 (en) 2008-03-31
CY1110348T1 (en) 2015-04-29
DK1886694T3 (en) 2009-09-28
PT1886694E (en) 2009-08-17
WO2008017331A3 (en) 2009-01-08
AR062323A1 (en) 2008-10-29
ES2327665T3 (en) 2009-11-02
SI1886694T1 (en) 2009-10-31
PL1886694T3 (en) 2009-11-30
CL2007002323A1 (en) 2008-02-15
EP1886694B1 (en) 2009-06-03
WO2008017331A2 (en) 2008-02-14
EP1886694A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
MY169516A (en) Pharmaceutical composition containing a tetrahydrofolic acid
TW200740427A (en) Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
RS51563B (en) Pharmaceutical compositions containing rosuvastatin calcium
WO2007022022A3 (en) Volumizing agents
BRPI0507342A (en) stabilized supersaturated solids of lipophilic drugs
RS53554B1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
HUP0400646A2 (en) Steroid hormone-compositions and processes for their preparation
EP1918780A3 (en) Toner compositions
CR9803A (en) SPREADING AGENTS FILM TRAINERS
GEP20135986B (en) Novel sustained release composition of compounds selected from class of centrally acting muscle relaxants
SG158181A1 (en) Improvements relating to polymeric compositions
PE20070327A1 (en) COMPOSITION INCLUDING A PROGESTIN AND A ESTROGEN
ECSP055629A (en) COMPOSITION CONTAINING AN ANDROGEN 11ß-HALOGENATED STEROID AND A GESTAGEN AS WELL AS A MALE CONTRACEPTIVE ON THE BASIS OF THESE COMPOSITIONS
CA2508824A1 (en) Alpha crystalline form of strontium ranelate, its preparation process, and the pharmaceutical compositions that contain it
MX2008001645A (en) Oral pharmaceutical suspension compositions of fexofenadine.
PE20080400A1 (en) PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS
JP2010539153A5 (en)
HRP20090438T1 (en) Peroral formulation of dienogest and ethinylestradiol for contraception
EP2210888A3 (en) Stable micronized candesartan cilexetil and methods for preparing thereof
GT200500122A (en) STEROID PROPHARMS WITH ANDROGENIC ACTION
BRPI0412391A (en) pharmaceutical formulation comprising sodium levothyroxine
RS51115B (en) Oral formulations of cladribine
PE20010579A1 (en) MESOPROGESTINES (PROGESTERONE RECEPTOR MODULARS) AS COMPONENTS OF FEMALE CONTRACEPTIVES
BR0116083A (en) Application device
IL195531A0 (en) Oral pharmaceutical composition of a poorly water-soluble active substance